In mice with subcutaneous KPC tumors, treatment with anti‐PD‐1 or anti‐CTLA‐4 enhanced the anti‐tumor effects of chemotherapy and agonist CD40 treatment. This evidence concerns the gene CTLA4 and neoplasm.